Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;87(10):948-52.
doi: 10.1177/154405910808701008.

Neuropeptide Y Y1 receptor effects on pulpal nociceptors

Affiliations

Neuropeptide Y Y1 receptor effects on pulpal nociceptors

J L Gibbs et al. J Dent Res. 2008 Oct.

Abstract

Neuropeptide Y (NPY) is an important modulatory neuropeptide that regulates several physiological systems, including the activity of sensory neurons. We evaluated whether activation of the NPY Y1 receptor could modulate the activity of capsaicin-sensitive nociceptors in trigeminal ganglia and dental pulp. We tested this hypothesis by measuring capsaicin-stimulated calcitonin gene-related peptide release (CGRP) as a measure of nociceptor activity. Capsaicin-evoked CGRP release was inhibited by 50% (p < 0.05) in trigeminal ganglia and by 26% (p < 0.05) in dental pulp when tissues were pre-treated with [Leu(31),Pro(34)]NPY. The Y1 receptor was found to co-localize with the capsaicin receptor TRPV1 in trigeminal ganglia. These results demonstrate that activation of the Y1 receptor results in the inhibition of the activity of capsaicin-sensitive nociceptors in the trigeminal ganglia and dental pulp. These findings are relevant to the physiological modulation of dental nociceptors by endogenous NPY and demonstrate an important novel analgesic target for the treatment of dental pain.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of [Leu31,Pro34]NPY on capsaicin-stimulated CGRP release from trigeminal ganglia. Freshly isolated ganglia were chopped and placed in perfusion chambers. Tissues were pre-treated with the Y1 agonist [Leu31,Pro34]NPY (30 nM) for 1 fraction (7 min). Tissues were then co-treated with [Leu31,Pro34]NPY (30 nM) and capsaicin (30 μM) for 1 fraction (7 min). Data are presented as fold-increase over baseline (BL), where the baseline represents the average CGRP release from the first 3 fractions (mean BL = 53.1 ± 4.0 fmol/mL). Statistical analysis by two-way ANOVA demonstrated a significant effect of drug treatment (F = 5.35, p < 0.05) and time (F = 8.21, p < 0.0001) on the measured outcome of CGRP release. A Bonferroni post hoc test demonstrates that the agonist-treated tissues released significantly less CGRP when stimulated by capsaicin in fraction 6 compared with vehicle-treated (veh) tissues (p < 0.001). Error bars = SEM. N = 15.
Figure 2
Figure 2
Effect of [Leu31,Pro34]NPY on peak capsaicin-stimulated CGRP release from trigeminal ganglia and dental pulp. Data are presented as fold-increase over baseline (BL), where baseline represents the average CGRP release prior to drug treatment (3 fractions in trigeminal ganglia and 5 fractions in dental pulp; BL = 53.1 ± 4.0 fmol/mL for trigeminal ganglia and 4.6 ± 0.3 fmol/mL for dental pulp). Statistical analysis by an unpaired two-tailed t test demonstrated that tissues pre-treated with [Leu31,Pro34]NPY (30 nM) released significantly less CGRP when stimulated with capsaicin (30 μM in trigeminal ganglia and dental pulp) (p < 0.05 for trigeminal ganglia and dental pulp). Error bars = SEM. N = 13 for trigeminal ganglia; n = 18 for dental pulp.
Figure 3
Figure 3
Co-localization of TRPV1 receptor immunoreactivity (green) with Y1 receptor immunoreactivity (red) in rat trigeminal ganglia (magnification = 20X). White arrows indicate examples of cells demonstrating co-localization. The co-localization of the Y1 receptor with the TRPV1 receptor indicates that Y1 receptors are localized on capsaicin-sensitive nociceptors.

Similar articles

Cited by

References

    1. Brain SD, Cox HM. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol. 2006;147(Suppl 1):202–211. - PMC - PubMed
    1. Brumovsky P, Shi TS, Landry M, Villar MJ, Hokfelt T. Neuropeptide tyrosine and pain. Trends Pharmacol Sci. 2007;28:93–102. - PubMed
    1. Caviedes-Bucheli J, Lombana N, Azuero-Holguin MM, Munoz HR. Quantification of neuropeptides (calcitonin gene-related peptide, substance P, neurokinin A, neuropeptide Y and vasoactive intestinal polypeptide) expressed in healthy and inflamed human dental pulp. Int Endod J. 2006;39:394–400. - PubMed
    1. El Karim IA, Lamey PJ, Linden GJ, Awawdeh LA, Lundy FT. Caries-induced changes in the expression of pulpal neuropeptide Y. Eur J Oral Sci. 2006;114:133–137. - PubMed
    1. Ericsson A, Hemsen A, Lundberg JM, Persson H. Detection of neuropeptide Y-like immunoreactivity and messenger RNA in rat platelets: the effects of vinblastine, reserpine, and dexamethasone on NPY expression in blood cells. Exp Cell Res. 1991;192:604–611. - PubMed

Publication types

MeSH terms